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DMD #22186 INTRODUCTION
CYP2C9 is a major form of human liver P450 involved in the metabolism of ~15% of all therapeutic agents that are cleared by oxidative metabolic processes (Williams et al., 2004) .
Many of these drugs, including (S)-warfarin, phenytoin and a wide variety of non-steroidal antiinflammatory (NSAID) drugs are hydrophobic and weakly acidic (Miners and Birkett, 1998; Rettie and Jones, 2005) . Early site-directed mutagenesis studies suggested that CYP2C9 residues, F114, V113, and F476 were involved in hydrophobic interactions with the substrates (S)-warfarin, diclofenac and the competitive inhibitor sulfaphenazole (Haining et al., 1999; Melet et al., 2003) .
In addition, the I helix residues S286 and N289 have also been implicated as important determinants of CYP2C9-dependent NSAID metabolism and high affinity sulfaphenazole binding (Jung et al., 1998; Klose et al., 1998) . Mutagenesis of the charged residues at R97, R108, D293 and D360 were also found to alter CYP2C9 substrate binding and metabolism (Ridderstrom et al., 2000; Flanagan et al., 2003; Dickmann et al., 2004) . In particular, the R108A mutant displayed a 100-fold lower activity towards diclofenac compared to wild-type (Ridderstrom et al., 2000) , and previous studies from this laboratory demonstrated that the R108F mutant exhibited diminished catalytic activity towards acidic diclofenac and (S)-warfarin, while maintaining most of the wild-type activity towards the uncharged molecule, pyrene (Dickmann et al., 2004) . This latter finding of ligand-dependent activity changes demonstrated that activity alterations were not a global phenomenon and indicated that R108 plays a critical role in the acid substrate selectivity of CYP2C9. Moreover, the crystal structure of CYP2C9 with flurbiprofen bound reveals that a side-chain nitrogen on R108 forms a salt bridge with the carboxylate of
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flurbiprofen (Wester et al., 2004) , thereby cementing the critical role of R108 in CYP2C9 selectivity for organic anions.
The above findings prompt the question, can charge-reversal at this site alter ligand specificity for CYP2C9? Literature precedent exists for this scenario in studies conducted previously with CYP2D6. In contrast to CYP2C9, CYP2D6 exhibits a well recognized preference for the binding and metabolism of basic compounds. Site-directed mutagenesis studies have implicated the charged acidic residues, E216 and D301 in providing critical electrostatic interactions with basic ligands (Ellis et al., 1995; Guengerich et al., 2002) . This interpretation appears compatible with the ligand-free crystal structure of CYP2D6 (Rowland et al., 2006) . Although wild-type CYP2D6 is incapable of metabolizing the NSAID diclofenac, the CYP2D6 E216Q/D301Q double mutant gained up to 16% of CYP2C9's activity towards this substrate . These data underscore the importance of these acidic residues in CYP2D6 for the binding and metabolism of basic compounds and encouraged us to attempt a similar approach to the rational re-engineering of CYP2C9's substrate specificity by targeting the critical R108 residue. We also examined the influence of D293 because this I-helix residue maps to D301 in CYP2D6 and forms a hydrogen bond with R108 when flurbiprofen is bound in the active site (Wester et al., 2004) .
The study design involved charge reversal and neutralization of these apparently critical charged amino acids in the active site of CYP2C9, and so the R108E and R108E/D293N double mutants were expressed in insect cells and purified to near homogeneity. These proteins were used in comparison to wild-type CYP2D6 and CYP2C9 to explore the metabolism (and in some DMD #22186 6 cases spectral binding) of the control ligands -diclofenac, pyrene and S-warfarin, ibuprofen amine -a 'designer' drug wherein the carboxylate of the CYP2C9 substrate ibuprofen has been replaced with a basic amine, and propranolol -a prototypic CYP2D6 substrate (see Figure 1 ).

MATERIALS AND METHODS
Chemicals and Reagents. 4-Hydroxy propranolol, 5-hydroxy propranolol and desisopropyl propranolol metabolites were gifts from Dr. Wendel L. Nelson (University of Washington).
Ibuprofen amine was synthesized as previously described (Davies et al., 2004) . Oligonucleotides, dNTPs and CELLFECTIN® reagent were purchased from Invitrogen (Carlsbad, CA). Restriction enzymes were purchased from New England BioLabs (Beverly, MA). EX-CELL TM 420 insect serum-free medium was purchased from JRH Bioscience, Inc. (Lenexa, KS). Octyl-Sepharose, δ−aminolevulinic acid, ferric citrate, dithiothreitol, sodium dithionite, NADPH and diclofenac were obtained from Sigma-Aldrich (St. Louis, MO). 4'-hydroxydiclofenac was provided by Novartis (Basel, Switzerland). Hydroxyapatite was purchased from Bio-Rad (Hercules, CA).
Pyrene and 1-hydroxypyrene were purchased from Supelco (Bellefonte, PA) and Acros Organics (Santa Clara, CA), respectively. (S)-Warfarin was obtained by fractional crystallization and deuterium labeled 3'-, 4'-, 6-, 7-and 8-hydroxy warfarins were synthesized as described previously (Bush and Trager, 1983) . Dilaurylphosphatidylcholine (DLPC) was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). HPLC grade solvents were from Fisher Scientific Co.
(Fair Lawn, NJ).
Protein Expression. CYP2C9 was subcloned into the pFastBac vector. Mutagenesis was performed using overlap extension PCR for the R108E mutation and QuikChange® II XL δ−Aminolevulinic acid and ferric citrate were added to the cell media at 0.3 mM and 0.2 mM, final concentrations respectively, after the cells had been infected for 16 to 24 hours.
Enzyme Preparations. Purification of wild-type CYP2C9 and the R108E, R108E/D293N mutants were carried out as described previously (Haining et al., 1999) on Octyl-Sepharose and hydroxyapatite with omission of the DEAE-Sepharose step. P450 spectral measurements (Estabrook and Werringloer, 1978) were taken with an Agilent 8453E UV-visible spectrometer.
Protein concentrations were measured by the Lowry method (Lowry et al., 1951) .
Protein Mass Spectrometry. LC/ESI-MS analysis was performed to obtain the mass of the mutant proteins as described previously (Henne et al., 2001 the thermally-induced conversion of P450 to P420 were determined according to the first order decay kinetics as previously described (Dickmann et al., 2004) . 
Metabolic Assays.
Diclofenac 4'-hydroxylation and Pyrene 1-Hydroxylation
These were performed according to the HPLC-UV (diclofenac) and HPLC-fluorescence (pyrene) assays described previously (Dickmann et al., 2004) .
(S)-Warfarin Hydroxylation
(S)-Warfarin metabolite profiling and subsequent steady-state kinetic studies were carried out by LC/MS assay using an Agilent Technologies LC/MSD series 1100 quadrupole mass spectrometer (Agilent, Palo Alto, CA) equipped with an Inertsil® ODS-3 analytical column (2.1 x 150 mm I.D., 5 µm particle size, GL Sciences Inc., Japan). Concentrations were 100 µM for the metabolite profiling studies. Deuterium labeled 4'-, 6-, 7-and 8-hydroxy warfarins (10-100 ng)
were used as internal standards. The mobile phases were: (A) 1.5% acetic acid in water (pH 4.7)
This article has not been copyedited and formatted. The final version may differ from this version. . Under these conditions, 4'-hydroxywarfarin eluted at ~8 min, 3'-hydroxywarfarin at ~9 min, 6-hydroxywarfarin at ~10 min,
8-hydroxywarfarin at ~13 min and 7-hydroxywarfarin at ~14 min. GraphPad Prism 4 (GraphPad Software. Inc., San Diego, CA) was used for kinetic analysis.
Propranolol Hydroxylation and N-Dealkylation
Propranolol concentrations ranged from 1-100 µM and 50-2000 µM for determination of K M and
Vmax for CYP2D6 and CYP2C9 (including its mutants), respectively. Enzymatic reactions were initiated by the addition of NADPH and allowed to proceed at 37 °C for 5 to 30 minutes. 10 µl of 70% perchloric acid was added to terminate reactions followed by 10 µl of 5 mg/ml solution of ascorbic acid to stabilize the hydroxylated propranolol metabolites. Racemic propranolol and its hydroxylated metabolites, 4-hydroxypropranolol (4-OH P), 5-hydroxypropranolol (5-OH P) and the N-dealkylated metabolite desisopropylpropranolol (DIP), were separated on an XTerra RP18 analytical column (5 µm / 4.6 x 150mm) using a protocol modified from a published procedure (Upthagrove and Nelson, 2001) . Analysis was carried out using a Shimadzu LC instrument equipped with an RF-10A XL fluorescence detector. Mobile phases were 0.2% TEA and 0.5% phosphoric acid (pH 2.2) (A) and acetonitrile (B). Gradient runs were programmed as follows: 0 to 10min, 10% to 20% B; 11 to 20 min, 20% to 70% B. The effluent was monitored fluorometrically with an excitation wavelength of 295nm and an emission wavelength of 380nm at a flow rate 1 ml/min. Under these conditions, 5-OH P eluted at13 minutes, 4-OH P at 14
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LC/MS Assay for Ibuprofen Amine Metabolism
Exploratory metabolic incubations were conducted with up to 100 µM substrate and 200 pmole P450. After 30 min at 37ºC, reactions were extracted at either pH 7 or pH 10 using 3 x 2 ml ethyl ether. Extracts were dried under nitrogen and reconstituted with 50 µl acetonitrile for MS analysis on a Micromass Quattro II tandem quadrupole mass spectrometer (Micromass, Ltd., Manchester, U.K.) equipped with a Zorbax RX-C8 analytical column (2.1 x 150 mm I.D., 5 µm particle size, Agilent). The mobile phases were: (A) 0.05% TFA in water and (B) 100%
acetonitrile. Gradient runs were programmed as follows: from 0 to 15min, 30% B to 40% B; then 100% B for 2min. Flow-rate was 1 ml/min but split such that 0.2 ml min -1 flowed into the mass spectrometer. Under these conditions, ibuprofen amine eluted at ~13 min. Ibuprofen amine and potential hydroxy metabolites were detected by LC/MS in the selected ion recording mode. with an error of <0.015%. Specific heme contents ranged from 3.4 -11 nmole/mg protein, with the lowest specific contents evident for the single and double mutants. The half-lives for thermally-induced conversion of P450 to P420 also decreased with the mutant proteins.
Collectively, these data demonstrate that charge reversal/neutralization at these active site residues is tolerated by CYP2C9, but the mutant proteins demonstrate decreased stability and heme incorporation relative to the wild-type enzyme.
Functional Activities of CYP2C9 Mutants.
The functional capabilities of the three CYP2C9 preparations were investigated with several types of ligands.
Control Ligands.
Metabolism of the prototypic acidic CYP2C9 substrates, (S)-warfarin and diclofenac, were tested together with the uncharged planar aromatic compound, pyrene.
Reactions were conducted at single substrate concentrations (50 -100 µM) that were well in excess of the wild-type K M for each ligand. Compared to native CYP2C9, the R108E mutant This article has not been copyedited and formatted. The final version may differ from this version. displayed very little activity toward (S)-warfarin and diclofenac, whereas the metabolism of pyrene was unchanged (Figure 2 ). These data demonstrate that R108E is a catalytically competent enzyme and that charge reversal provides the metabolic profile towards acidic and uncharged substrates expected from earlier studies with the R108F mutant (Dickmann et al., 2004) . In contrast, the R108E/D293N retained 10-30% activity towards S-warfarin, diclofenac and pyrene, indicating that the double mutant possesses little of the ligand dependence evident for the R108E mutant.
Propranolol. Propranolol metabolism was analyzed because it is a well recognized substrate for CYP2D6 forming multiple products (Nelson and Burke, 1978; Talaat and Nelson, 1988 ). In the current study, CYP2D6 displayed a high turnover number for propranolol (~70 min -1 ), and favored aromatic hydroxylation over N-dealkylation by a factor of >15: 1 (Figure 3 ). These data confirm that, under catalytic conditions, the propranolol molecule is principally oriented in CYP2D6 with the basic nitrogen directed away from the heme iron. In contrast, wild-type CYP2C9 displayed low activity and practically no regioselective metabolism of propranolol ( Figure 3) . Disappointingly, the R108E mutant showed no tendency towards a CYP2D6 profile, either in terms of regioselectivity of metabolism or catalytic efficiency ( Figure 3 and Table 2 ).
The R108E/D293N double mutant did exhibit a slight increase in propranolol turnover coupled with a shift in the regioselectivity that appeared to better favor a CYP2D6 profile (Figure 3, insert). However, a more detailed kinetic study revealed no gain in efficiency of propranolol metabolism by this CYP2C9 mutant (Table 2) .
Ibuprofen Amine Analog.
Because this analog has the same skeleton as ibuprofen, a prototypical CYP2C9 substrate, it was thought that CYP2C9 mutants might be better able to adapt to binding of the amine derivative of this molecule than to binding of the propranolol. 
DISCUSSION
The objective of this study was to alter the substrate selectivity of CYP2C9 towards basic ligands by site-directed mutagenesis of key active site amino acids known to bind acidic substrates like flurbiprofen (Wester et al., 2004) . Many examples of successful re-engineering of other enzyme activities are known. For example, reciprocally switching amino acids F208 in rat monoamine oxidase (MAO) A and its corresponding residue in rat MAO B, I199, was sufficient to switch the substrate and inhibitor preferences of rat MAO-A and MAO-B (Tsugeno and Ito, 1997) . Moreover, as noted earlier, in the P450 field, Wolf and coworkers showed that a CYP2D6 double mutant E216Q/D301Q, was able to confer upon the enzyme modest CYP2C9-like diclofenac 4'-hydroxylase activity, although the overall catalytic efficiency achieved was only ~1% that of wild-type CYP2C9 . The present study design drew on the (partial) success of the CYP2D6 mutagenesis experiments as we attempted to increase the selectivity of CYP2C9 for basic ligands, by charge reversal and neutralization of R108 and D293, respectively.
Data from both site-directed mutagenesis and the flurbiprofen-bound CYP2C9 crystal structure indicate that the positively charged R108 interacts electrostatically with the carboxylic acid group of the NSAID (Dickmann et al., 2004; Wester et al., 2004 charged D293. Therefore, we also expressed and purified the E108/N293 double mutant to neutralize any potential charge repellency. Fairly conservative changes at D293 are necessary because of the apparent role of this amino acid in protein stability Dickmann et al., 2004) , which were further highlighted in the present study (Table 1) . Both the single and double mutants expressed reasonably well in insect cells, however, the low specific heme contents and increased thermal lability, relative to wild-type CYP2C9, suggest that these mutations place a strain on the active site environment and hinder holo-enzyme formation.
Consequently, additional mutagenesis involving other potentially interacting active-site residues, such as N289, were not pursued at this time.
Functional data for 'control' ligands demonstrated that, as expected, the R108E mutant lost activity towards (S)-warfarin and diclofenac, but maintained activity towards the uncharged molecule, pyrene (Figure 2) . However, when metabolism of the prototypic CYP2D6 substrate propranolol was examined, the R108E single mutant exhibited the same low degree of turnover and lack of regioselectivity displayed by wild-type CYP2C9. Some slight improvement was evident with the double mutant in that regioselectivity shifted towards a CYP2D6 profile where aromatic hydroxylation predominates over N-dealkylation. Closer examination of the kinetics for these reactions, however, provided no indication of enhanced CYP2D6-type catalysis ( Table   2) .
One of the 'control" ligands whose metabolism was examined is (S)-warfarin. It has been suggested that warfarin interacts with CYP2C9 as a ring-closed hemiketal, which is less acidic than the ring-opened form (He et al., 1999) . Therefore, one might anticipate a reduced effect of This article has not been copyedited and formatted. The final version may differ from this version. mutations at R108 on (S)-warfarin metabolism. However, as had been seen previously for the R108F mutant (Dickmann et al., 2004) , (S)-warfarin metabolism was practically abolished by the R108E mutation. Possibly, R108 impacts (S)-warfarin metabolism through a different type of interaction, either with substrate or the other active site residues, or perhaps the different tautomeric forms interconvert in the active site. The detailed mechanism underlying these observations requires further investigation.
Prior to the availability of CYP2C9 crystal structures and the emergence of R108 as a key active site residue, Gillam and coworkers evaluated the role of two other basic amino acids, R97
and K72, in the ligand selectivity of CYP2C9 (Davies et al., 2004 ). An interesting approach used in this study was the attempted spectral characterization of the amine analogs of the classical CYP2C9 substrates, phenytoin, naproxen and ibuprofen with the mutant enzymes generated. The rationale here was that a re-engineered CYP2C9 active site might more readily accommodate a basic ligand that had the same skeleton as an established CYP2C9 substrate, and exhibit a Type I (substrate-like) spectrum. However, no classical spectral perturbations were obtained in this earlier study, perhaps due to the relatively low levels of enzyme expression obtained for many of the mutant proteins.
In the present study, relatively large amounts of purified enzymes and mutants were available, and so we also examined spectral binding of the ibuprofen amine analog to each of the CYP2C9 preparations. Ibuprofen amine bound tightly to wild-type CYP2C9 and exhibited the to charge-modified CYP2C9, as might be expected for CYP2D6. However, when considered together with reduced specific heme contents, enhanced thermal lability and a loss of ligandspecific metabolic effects, especially for R108E/D293N, this might simply be reflective of a more general disordering of the CYP2C9 active site in the mutant enzymes.
In summary, the functional studies conducted here further highlight the importance of the amino acid at position 108 in CYP2C9 in the binding and metabolism of acidic ligands.
However, despite the increasingly well documented conformational flexibility of mammalian P450 active sites (Ekroos and Sjogren, 2006; Muralidhara et al., 2006) , and the experimentally demonstrated tolerance of significant change in electrostatic charge distribution within the CYP2C9 active site, the attempted re-engineering of CYP2C9's ligand selectivity by charge reversal at this key residue provided little gain in terms of a CYP2D6 profile that favors basic ligands. Interestingly, a recent report demonstrated that very extensive re-engineering (16 amino acid changes) was required to confer even modest (S)-mephenytoin 4'-hydroxylase activity -a CYP2C19 marker activity -on CYP2C9 (Wada et al., 2008) . This result speaks to the complex, and likely interactive, nature of mammalian P450 active sites, and suggests that successful reengineering of P450 substrate specificity across sub-families, as attempted here, will not be a trivial exercise.
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